<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="18257">Ornithine</z:chebi> transcarbamylase (OTC) deficiency is the most common <z:chebi fb="20" ids="16199">urea</z:chebi> cycle defect </plain></SENT>
<SENT sid="1" pm="."><plain>Thromboembolic complications have not heretofore been linked with this diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>We describe four patients with <z:hpo ids='HP_0003623'>neonatal-onset</z:hpo> OTC deficiency who developed vascular thromboses </plain></SENT>
<SENT sid="3" pm="."><plain>One patient had <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo>; the rest developed venous thromboses </plain></SENT>
<SENT sid="4" pm="."><plain>Multiple pro-thrombotic risk factors were identified </plain></SENT>
<SENT sid="5" pm="."><plain>Low plasma arginine levels were observed in <z:hpo ids='HP_0000001'>all</z:hpo> patients at the time of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Arginine deficiency and the resultant nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> insufficiency may contribute to thrombotic risk </plain></SENT>
<SENT sid="7" pm="."><plain>Careful normalization of plasma arginine and <z:chebi fb="0" ids="18211">citrulline</z:chebi> levels and increased surveillance for thrombotic complications should be considered in patients with OTC deficiency </plain></SENT>
</text></document>